Lipoprotein-Associated Phospholipase A2 Activity Level may be complementary to Cardiactroponin I as a Biomarker for Acute Myocardial Infarction in Chinese Patients with Chest Pain

Abstract

Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with increased atherosclerotic cardiovascular disease (ASCVD) risk, which relatively unique in its high specificity for vascular inflammation. So we study if Lp-PLA2 is independent of or complementary to cardiac troponin I (cTn I) as a risk predictor of acute myocardial infarction (AMI). Methods: Across-sectional analysis on 125 patients admitted to the cardiovascular department for acute chest pain, including age, gender, family history, smoking status, hypertension, diabetes mellitus, kidney function, cTn I, blood lipid and Lp-PLA2 activity. Univariate and multivariate logistic regression analyses and the Cox proportional hazards model were performed to identify the risk factors for ASCVD. Results: Lp-PLA2 activity was higher in AMI than stable / unstable angina pectoris (UA/SA). (173±59U/L vs 144±46U/L, P< 0.01).The area under the ROC curve (AUC) of Lp-PLA2 activity used to predict AMI was 0.649 (95% CI: 0.546 -0.752, P=0.007). The Lp-PLA2 cut-off value was 157 IU/L, and the sensitivity and specificity were 60% and 71%, respectively. Lp-PLA2 level was associated with the prevalence of AMI with an odds ratio (OR) of 2.723 [95% confidence interval (CI): 1.145-6.473, p=0.023] in multivariate analysis. Conclusion: Lp-PLA2activity was independent of cTnI and may be complementary to cTnI as an AMI risk marker.

Lipoprotein-associated phospholipase A2 in relation to lipid markers: A pan-India correlation study

“…2 The evidence of positive association has been proven in many ethnic groups with acute myocardial infarction, cardiovascular disease (CVD) as well as incidence of coronary heart disease. 7,8 LDLs are…”